Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 4-Week Low-Carb diet make liver surgery safer?

NCT ID NCT05884723

Disease control Sponsor: Anton Skaro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a 4-week ketogenic diet before liver surgery can reduce fat in the liver and lower the need for blood transfusions. About 124 adults with fatty liver and colorectal cancer that spread to the liver will either follow the diet or get standard dietary advice. The goal is to see if the diet makes surgery safer by reducing liver fat and bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ketogenic diet (very low carbohydrate, high fat, moderate protein)
What this could lead to
If successful, this diet could become a standard short-term preparation to make liver surgery safer for patients with fatty liver.
What could go wrong
This is an early-stage trial with 124 participants, so results may not apply to everyone. The diet is strict and may be hard to follow, and it is not a treatment for the underlying liver disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18 years of age or older undergoing any type of liver resection (e.g. wedge, formal hepatectomy), either open or laparoscopic, for colorectal liver metastases (CRLM) * Patients with evidence of hepatic steatosis on pre-operative imaging (CT or MR) or biopsy. * Ability to use an app based nutritional program to track macronutrient uptake throughout the dietary intervention. Exclusion Criteria: * Patients undergoing liver resection for any other indication * Patients on sodium glucose co-transporter 2 (SGLT-2) inhibitors (these are contraindicated with a ketogenic diet). * Patients without evidence of hepatic steatosis. * Patients with evidence of liver fibrosis or cirrhosis on preoperative bloodwork or imaging. * Patients with alcohol-related hepatic steatosis. * Patients with a known bleeding disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver metastasis colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatotic liver disease metastasis from malignant tumor of colon

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver metastasis colon cancer Liver steatoses NAFLD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • London Health Sciences Centre/Western University

    RECRUITING

    London, Ontario, N6A 5A5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.